Japan Chemical Research Looks To Grow Market Shares For Growth Hormone Products
This article was originally published in PharmAsia News
Japan Chemical Research 2008 sales increased by 1.8 percent to ¥12.82 billion, through growth of the company's major product, human growth hormone Growject (somatropin). For fiscal year 2009, the company estimates a 1.8 percent increase in sales and 8 percent increase in income. JCR submitted a new drug application in Japan for recombinant erythropoietin to treat nephrogenic anemia last November, aiming for a market launch in 2010. JCR also begins clinical trials for its mesenchymal stem cell therapeutic agent in Japan. (Click here for more - Japanese language
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.